Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Eli Lilly and Company Limited
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
An exploratory Phase 2 study of Pemetrexed and Cisplatin as Preoperative chemotherapy in the treatment of Stage IIIAN2 nonsquamous non-Small cell lung cancer
Assess the antitumor activity of pemetrexed in combination with cisplatin, as measured by Overall Response Rate after preoperative chemotherapy, in patients with stage IIIAN2 nonsquamous NSCLC
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
to assess the long-term maintenance of efficacy of duloxetine 60 to 120 mg once daily (QD) compared with placebo by a comparison of the time to relapse among patients with Diagnostic and Statistical M...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
Efficacy of Once-Weekly Exenatide versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea
The primary objective of this study is to test the hypothesis that exenatide QW given once weekly for 26 weeks is superior to a titration of insulin detemir, given once or twice daily (titrated to rea...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Feasibility study of Pemetrexed single agent and folic acid given as neoadjuvant treatment in patients with resectable rectal cancer
To evaluate the feasibility of three neo-adjuvant cycles of single agent Pemetrexed at 500 mg/m2 q3w prior to surgery with or without radiotherapy in patients with resectable rectal cancer.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Treatment-Naïve Children and Adolescents. (ADHD-LIFE Study)
The primary objective is to test the hypothesis that atomoxetine given at individually titrated doses for 6 months is superior to other early standard therapy in improving quality of life as measured ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
To estimate the difference in change in HbA1c from the randomization visit (visit 2) to endpoint (30 weeks) between 2 regimens: BET (basal insulin Glargine, Exenatide BID and metformin) and BBT (basal...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
Comparison of Two Different Treatment Strategies in Patients with Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy
This study has two primary objectives: (1) to test the hypothesis that time to confirmed response is shorter in the early intervention strategy vs. the delayed intervention strategy, among patients id...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer
Main objective :To estimate the 6-month (24 weeks) progression-free survival for patients with metastatic CRC who are treated with enzastaurin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
To compare Arm A versus Arm B in terms of PFS measured from the time of randomization after completing 6 cycles of first-line therapy for metastatic CRC: • Arm A: 5-FU/LV plus bevacizumab in combinat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer
To estimate the time-to-progressive disease for patients who have received LY573636 after two prior treatment regimens of systemic therapy for unresectable, metastatic non-small cell lung cancer (NSCL...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
4
5
6
Next